mesalamine has been researched along with rosiglitazone in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Brun, P; Carta, D; Castagliuolo, I; Dean, A; Di Marco, V; Ferlin, MG; Surajit, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Liang, HL; Ouyang, Q | 1 |
| Brynskov, J; Pedersen, G | 1 |
1 review(s) available for mesalamine and rosiglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for mesalamine and rosiglitazone
| Article | Year |
|---|---|
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Mesalamine; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Blotting, Western; Colitis, Ulcerative; Colonoscopy; Enema; Female; Humans; Hypoglycemic Agents; Male; Membrane Proteins; Mesalamine; Middle Aged; Peptides; Perilipin-2; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones | 2010 |
4 other study(ies) available for mesalamine and rosiglitazone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Peroxisome proliferator-activated receptor-γ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: synthesis and biological evaluation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Dose-Response Relationship, Drug; Humans; Isonicotinic Acids; Lipopolysaccharides; Macrophages; Molecular Structure; PPAR gamma; RNA, Messenger; Structure-Activity Relationship; Transcription, Genetic | 2013 |